Studies for a new COVID-19 vaccine made by China’s Clover Biopharmaceuticals have shown an efficacy of 79 percent against the highly infectious delta variant.
Citing a study conducted by the company on Wednesday, a statement said that the protein-based vaccine candidate, known as SCB-2019, was found to be 67 percent effective overall against coronavirus infections of any severity. Gaya. .
According to the study, SCB-2019 was also 92 percent effective against the Gamma variant and 59 percent effective against the Mu variant.
Collectively, these three strains comprised “73 percent of all strains identified in the study.”
“We are delighted that SCB-2019 has performed successfully against the dominant Delta strain and other related variants globally,” said Joshua Liang, Clover CEO, in the statement.
“This is the first vaccine candidate to demonstrate significant efficacy against all three of these variants. Differences in vaccine efficacy across variant strains are driven by each variant’s unique mutation profile, which makes some strains more transmissible and/or sparser than others.” may and may be able to evade immunity,” the company said.
Clover, which has a deal to supply about 414 million doses of its coronavirus vaccines through Covax’s global vaccine sharing plan, submitted trial data for conditional approval to the World Health Organization and regulators in China and Europe in the last quarter of this year. Will do Year.
The company received $328m in funding from the Coalition for Epidemic Preparedness Innovation (CEPI) for vaccine development. CEPI has previously endorsed the AstraZeneca and Moderna COVID vaccines.
The pharmaceutical company enrolled more than 30,000 adults from 31 sites in the Philippines, Brazil, Colombia, South Africa and Belgium for its clinical trial in which candidates received either a random dose of SCB-2019 or a placebo in a two-dose regimen was administered over 21 days. Separate.
The trial was conducted from April 28 to August 10 this year, where scientists tested the vaccine’s efficacy, safety and immunogenicity, according to the organization.
An independent Endpoint Decision Committee ruled on a total of 207 symptomatic COVID-19 cases that were reported at least two weeks after the second dose in the larger trial. The participants in the trial had not previously contracted the coronavirus infection.
Of the total cases, 52 were from a vaccination group, while the remaining 155 formed the placebo group.
The trial found that there were no cases of hospitalization due to COVID and no cases of severe disease in the vaccine group, resulting in 100 percent efficacy against hospitalization and severe coronavirus infection.
The vaccine has an 83.7 percent efficacy against moderate to severe coronavirus infection against any type of infection. According to the study, however, three deaths were reported in the placebo group.
Clover said enrollment of elderly participants in the trial was limited because vaccination campaigns to vaccinate the elderly population had already begun in countries where Clover was recruiting participants.
It said that all five cases of Kovid in participants 65 years of age or older occurred in the placebo or non-vaccine group.
Of the total participants, about 18 percent had comorbidities, but the trial saw no difference in vaccine efficacy among participants with or without comorbidities.
Credit: www.independent.co.uk /